IP Library Granted Patent US 11,442,061
Granted Patent B2
US 11,442,061 · App. 15/951,769 · Granted Sep 13, 2022

Reducing optical interference in a fluidic device

Inventors: Ian Gibbons; Michael O'Connell (San Jose, CA)
Assignee: Labrador Diagnostics LLC
G01N33/5304B01L3/5027B01L3/502715G01N33/536B01L2200/16B01L2300/069B01L2300/0816B01L2300/0887B01L2400/0406B01L2400/0487Y10T156/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,442,061
App. No.
15/951,769
Granted
Sep 13, 2022
Kind
B2
Abstract

This invention is in the field of medical devices. Specifically, the present invention provides portable medical devices that allow real-time detection of analytes from a biological fluid. The methods and devices are particularly useful for providing point-of-care testing for a variety of medical applications. In particular, the medical device reduces interference with an optical signal which is indicative of the presence of an analyte in a bodily sample.

Claims (29)

1. A system for detecting an analyte in a sample of bodily fluid, the system comprising:

a sample collection unit configured to receive the sample of bodily fluid;

an assay assembly in fluidic communication with the sample collection unit, the assay assembly comprising a reagent chamber, a reaction site, and a fluidic channel that connects the reagent chamber with the reaction site, wherein a reactant is immobilized in the reaction site, and wherein the reagent chamber comprises a reagent;

a waste chamber in fluidic communication with, but spaced apart from, the assay assembly, wherein the waste chamber comprises absorbent material configured to absorb waste liquids from the assay assembly such that optical interference of a fluorescent signal from the waste liquids is reduced, wherein the absorbent material is impregnated with a quenching agent, wherein the quenching agent inhibits an enzymatic reaction between the reagent and a second reagent, thereby reducing the optical interference; and

a reader assembly comprising a controller, a detection assembly, and an actuating element configured to effect movements between the sample collection unit, the assay assembly, and the waste chamber, wherein the movements include:

moving the sample through the sample collection unit to the assay assembly, such that the sample is allowed to react with the reactant immobilized in the reaction site;

moving unreacted reactant from the assay assembly to the waste chamber; and

moving the reagent from the reagent chamber to the reaction site through the fluidic channel,

wherein the assay assembly is configured to yield a fluorescent signal indicative of the presence of the analyte in the sample, wherein the fluorescent signal results from a reaction between the sample and at least one of the reactant or the reagent; and

wherein the detection assembly is configured to detect the analyte in the sample by detecting the fluorescent signal.

2. The system of claim 1 , wherein the actuating element comprises one of a pump and a valve.

3. The system of claim 1 , wherein the detection assembly comprises one of a digital camera, a charge coupled device (CCD), a photomultiplier, or a phototube.

4. The system of claim 1 , wherein the reactant comprises an antibody that reacts with the analyte.

5. The system of claim 1 , wherein the sample of bodily fluid comprises blood.

6. The system of claim 1 , wherein the reagent comprises one of an enzyme conjugate and an enzyme substrate.

7. A fluidic device having a housing and being configured to run an assay for detecting an analyte in a sample of bodily fluid within the housing, the fluidic device comprising:

a sample collection unit configured to receive the sample of bodily fluid;

an assay assembly in fluidic communication with the sample collection unit, the assay assembly comprising a reagent chamber, a reaction site, a first fluidic channel that connects the sample collection unit to the assay assembly, a second fluidic channel that connects the assay assembly to the waste chamber, and a third fluidic channel that connects the reagent chamber with the reaction site, wherein a reactant is immobilized in the reaction site, and wherein the reagent chamber comprises a reagent; and

a waste chamber in fluidic communication with, but spaced apart from, the assay assembly, wherein the waste chamber comprises absorbent material configured to absorb waste liquids from the assay assembly such that optical interference of a fluorescent signal from the waste liquids is reduced, wherein the absorbent material is impregnated with a quenching agent, wherein the quenching agent inhibits an enzymatic reaction between the reagent and a second reagent, thereby reducing the optical interference,

wherein the assay assembly is configured to:

receive the sample from the sample collection unit, wherein the sample is moved from the sample collection unit to the assay assembly through the first fluidic channel;

allow the sample to react with the reactant immobilized in the reaction site, wherein unreacted reactant is moved to the waste chamber through the second fluidic channel;

allow the reagent from the reagent chamber to react at the reaction site, wherein the reagent is moved from the reagent chamber to the reaction site through the third fluidic channel; and

yield a fluorescent signal indicative of the presence of the analyte in the sample, wherein the fluorescent signal results from a reaction between the sample and at least one of the reactant or the reagent.

8. The fluidic device of claim 7 , wherein movements between the sample collection unit, the assay assembly, and the waste chamber are effected by at least one of a pump or a valve of an actuating element.

9. The fluidic device of claim 7 , wherein the reactant comprises an antibody that reacts with the analyte.

10. The fluidic device of claim 7 , wherein the sample of bodily fluid is selected from the group consisting of blood, plasma, serum, saliva, urine, gastric and digestive fluid, tears, stool, semen, vaginal fluid, interstitial fluids derived from tumorous tissue, and cerebrospinal fluid.

11. The fluidic device of claim 7 , wherein the reagent comprises one of an enzyme conjugate and an enzyme substrate.

12. The fluidic device of claim 7 , wherein the analyte in the sample is detected via the fluorescent signal by one of a digital camera, a charge coupled device (CCD), a photomultiplier, or a phototube.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2022
From: GIBBONS, IAN; O'CONNELL, MICHAEL
To: THERANOS, INC.
Reel/Frame 061198/0219 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2022
From: THERANOS, INC.
To: THERANOS IP COMPANY, LLC
Reel/Frame 061521/0231 →
SECURITY INTEREST Recorded Sep 23, 2022
From: THERANOS IP COMPANY, LLC
To: FORTRESS CREDIT CORP.
Reel/Frame 061521/0627 →
CHANGE OF NAME Recorded Apr 7, 2020
From: THERANOS IP COMPANY LLC
To: LABRADOR DIAGNOSTICS LLC
Reel/Frame 052329/0716 →
Continuity (4)
Continuation 13915362 · Jun 11, 2013
Continuation 13188288 · Jul 21, 2011
Continuation 11549558 · Oct 13, 2006
Related Publication 20180231535A1 · Aug 16, 2018